Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Upgraded by StockNews.com

Esperion Therapeutics (NASDAQ:ESPR) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

Several other research analysts have also weighed in on the stock. Needham & Company LLC lowered their price objective on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Wednesday, October 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Esperion Therapeutics presently has an average rating of “Hold” and a consensus target price of $8.17.

Esperion Therapeutics Stock Performance

ESPR opened at $2.10 on Friday. The business’s 50-day simple moving average is $1.85 and its 200 day simple moving average is $2.12. Esperion Therapeutics has a 52-week low of $0.71 and a 52-week high of $3.40. The firm has a market capitalization of $412.08 million, a PE ratio of -2.44 and a beta of 1.00.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. The company had revenue of $73.83 million for the quarter, compared to the consensus estimate of $51.90 million. On average, research analysts forecast that Esperion Therapeutics will post -0.04 earnings per share for the current year.

Hedge Funds Weigh In On Esperion Therapeutics

Several large investors have recently modified their holdings of ESPR. Capital Advisors Wealth Management LLC grew its stake in Esperion Therapeutics by 22.9% in the 2nd quarter. Capital Advisors Wealth Management LLC now owns 26,800 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 5,000 shares during the last quarter. Boomfish Wealth Group LLC increased its stake in shares of Esperion Therapeutics by 17.1% during the third quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 5,102 shares during the period. Summit Financial LLC lifted its holdings in Esperion Therapeutics by 26.4% during the 2nd quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 6,823 shares during the last quarter. National Bank of Canada FI boosted its stake in Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 10,225 shares during the period. Finally, SG Americas Securities LLC grew its holdings in Esperion Therapeutics by 45.3% in the 2nd quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 11,658 shares in the last quarter. 47.39% of the stock is owned by institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.